BioLife Solutions (BioLife Solutions) Accounts Receivable : $18.6 Mil (As of Mar. 2024)

View and export this data going back to 1992. Start your Free Trial

What is BioLife Solutions Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. BioLife Solutions's accounts receivables for the quarter that ended in Mar. 2024 was $18.6 Mil.

Accounts receivable can be measured by Days Sales Outstanding. BioLife Solutions's Days Sales Outstanding for the quarter that ended in Mar. 2024 was 53.42.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. BioLife Solutions's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $0.28.

BioLife Solutions Accounts Receivable Historical Data

The historical data trend for BioLife Solutions's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLife Solutions Accounts Receivable Chart

BioLife Solutions Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Receivable

Get a 7-Day Free Trial

5.35

8.01

23.22

33.94

18.66

BioLife Solutions Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Receivable	Get a 7-Day Free Trial															30.34	26.86	24.56	18.66	18.57

BioLife Solutions Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

BioLife Solutions Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

BioLife Solutions's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	18.574	/	31.727	*	91
=	53.42

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), BioLife Solutions's accounts receivable are only considered to be worth 75% of book value:

BioLife Solutions's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(45.273	+	0.75 * 18.574	+	0.5 * 43.414	-	68.197
-	0	-	0)	/	45.6896
=	0.28

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

BioLife Solutions Accounts Receivable Related Terms

Thank you for viewing the detailed overview of BioLife Solutions's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

BioLife Solutions (BioLife Solutions) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BioLife Solutions Inc (NAS:BLFS) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

BJX1:Germany

Address

3303 Monte Villa Parkway, Suite 310, Bothell, WA, USA, 98021

Website

https://www.biolifesolutions.com

BioLife Solutions Inc is active in the healthcare segment. The company is engaged in developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud, hosted biologistics cold chain management application for shippers. The company's product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs.

Executives

Geraint Phillips	officer: SVP, Global Operations	3303 MONTE VILLA, #310, BOTHELL WA 98021
Sarah Aebersold	officer: VP, Global Human Resources	BIOLIFE SOLUTIONS, INC., 3303 MONTE VILLA PARKWAY, BOTHELL WA 98021
Troy Wichterman	officer: Chief Financial Officer	3303 MONTE VILLA PARKWAY, BOTHELL WA 98021
Greef Roderick De	director
Aby J. Mathew	officer: Chief Tech. Officer & Sr. VP	3303 MONTE VILLA PARKWAY, #310, BOTHELL WA 98021
Todd Berard	officer: Vice President, Marketing	3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL WA 98021
Karen A. Foster	officer: Vice President of Operations	C/O BIOLIFE SOLUTIONS, INC., 3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL WA 98021
Michael Rice	director, officer: President & CEO	C/O BIOLIFE SOLUTIONS, INC., 171 FRONT STREET, OWEGO NY 13827
Casdin Partners Master Fund, L.p.	10 percent owner	WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Garrie Richardson	officer: Chief Revenue Officer	3303 MONTE VILA PARKWAY, BOTHELL WA 98021
Marcus Schulz	officer: Vice President, Global Sales	3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL WA 98021
Joseph C Schick	director	16719 NE 139TH PLACE, WOODINVILLE WA 98072
Amy Duross	director	8410 GOLDEN BEAR PLACE, WHISTLER A1 V8E 1J7
Timothy L. Moore	director	C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404
Joydeep Goswami	director	SUMITOMO FUDOSAN MITA TWIN BLDG, EAST WING 4-2-8 SHIBAURA MINATO-KU, TOKYO M0 1080023